Safety and efficacy of NouvSoma001 for NMOSD
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new treatment called NouvSoma001 for neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the optic nerves and spinal cord. It looks at whether the drug is safe and helps people who have had a recent attack with severe pain, trouble walking, or bladder/bowel problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD and tested positive for AQP4 antibodies.
- Your current symptoms started within the last 7 days and include severe pain, leg weakness, or trouble controlling your bladder or bowels.
- You are between 18 and 65 years old.
- Before this episode, your disability from NMOSD was mild (an EDSS score of 4 or less).
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
This trial tests a new treatment called NouvSoma001 for people who have had an ischemic stroke within the last week. It aims to see if the treatment is safe and helps improve muscle strength and overall recovery.
This study tests whether a new stem cell treatment (CE211NS21) is safe and well-tolerated in patients who have had a recent serious attack from NMOSD, a rare neurological condition. The treatment aims to reduce disability and vision loss from this disease.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
Hear when a new Neuromyelitis Optica Spectrum Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.